Make your own free website on Tripod.com

Bibliography:

Research Papers, book chapters and reviews

  1. Korninger C, Stassen JM, Collen D. Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits. Thromb Haemostas 1981; 46: 658-61.

  2. Collen D, Matsuo O, Stassen JM, Kettner C, Shaw E. In vivo studies of a synthetic inhibitor of thrombin. J Lab Clin Med 1982; 99: 76-83.

  3. Korninger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in dogs with femoral vein thrombosis. J Clin Invest 1982; 69: 573-80.

  4. Collen D, Stassen JM, Verstraete M. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration. J Clin Invest 1983; 71: 368-76.

  5. Collen D, Stassen JM, Verstraete M: Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with jugular vein thrombosis, in Davidson JF, Bachman F, Bouvier CA, Kruithof EKO (eds): Progress in fibrinolysis, Edinburgh, Churchill Livingstone, 1983, pp 227-31.

  6. Collen D, Stassen JM, Blaber M, Winkler M, Verstraete M. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemostas 1984; 52: 27-30.

  7. Collen D, Stassen JM, Marafino BJ, Jr., Builder S, De Cock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J, et al. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharmacol Exp Ther 1984; 231: 146-52.

  8. Colucci M, Stassen JM, Collen D. Influence of protein C activation on blood coagulation and fibrinolysis in squirrel monkeys. J Clin Invest 1984; 74: 200-4.

  9. Colucci M, Stassen JM, Salwa J, Collen D. Identification of plasminogen activator releasing activity in the neurohypophysis. Br J Haematol 1984; 58: 337-46.

  10. Bounameaux H, Stassen JM, Seghers C, Collen D. Influence of fibrin and liver blood flow on the turnover and the systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator in rabbits. Blood 1986; 67: 1493-7.

  11. Collen D, Stassen JM, Stump DC, Verstraete M. Synergism of thrombolytic agents in vivo. Circulation 1986; 74: 838-42.

  12. Colucci M, Paramo JA, Stassen JM, Collen D. Influence of the fast-acting inhibitor of plasminogen activator on in vivo thrombolysis induced by tissue-type plasminogen activator in rabbits. Interference of tissue-derived components. J Clin Invest 1986; 78: 138-44.

  13. Collen D, Stassen JM, De Cock F. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Thromb Haemostas 1987; 58: 943-6.

  14. Juhan Vague I, Stassen JM, Alessi MC, De Cock F, Serradimigni A, Collen D. [Low molecular weight heparin CY 222 (Choay) potentiates the thrombolytic effect of 1-PA in rabbits with experimental thrombosis of the jugular vein]. J Mal Vasc 1987; 12 Suppl B: 64-5.

  15. Paulusma-de Waal JH, de Boer AC, Cox PH, Stassen JM, Collen D, Pillay M. Technetium labelled plasminogen activator - a potential reagent for thrombus detection. Nuc Compac 1987; 18: 284-6.

  16. Stassen JM, Juhan Vague I, Alessi MC, De Cock F, Collen D. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator. Thromb Haemostas 1987; 58: 947-50.

  17. Stump DC, Stassen JM, Demarsin E, Collen D. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator. Blood 1987; 69: 592-6.

  18. Collen D, Stassen JM, Larsen GR. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-9.

  19. Collen D, Mao J, Stassen JM, Broeze R, Lijnen HR, Abercrombie D, Puma P, Almeda S, Vovis G. Thrombolytic properties of Lys-158 mutants of recombinant single chain urokinase-type plasminogen activator (scu-PA) in rabbits with jugular vein thrombosis. J Vasc Med Biol 1989; 1: 46-9.

  20. Collen D, Stassen JM, Demarsin E, Kieckens L, Lijnen HR, Nelles L. Pharmacokinetics and thrombolytic properties of chimeric plasminogen activators consisting of the NH2-terminal region of human tissue-type plasminogen activator and the COOH-terminal region of human single chain urokinase-type plasminogen activator. J Vasc Med Biol 1989; 1: 234-40.

  21. Collen D, Dewerchin M, Stassen JM, Kieckens L, Lijnen HR. Pharmacokinetic and thrombolytic properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for crosslinked fibrin. Fibrinolysis 1989; 3: 197-202.

  22. Hashimoto Y, Stassen JM, Leclef B, De Roo M, Vandecruys A, Melin J, Verhoeven Mester D, Trouet A, Collen D. Thrombus imaging with an I-123-labeled F(ab')2 fragment of an anti-human fibrin monoclonal antibody in a rabbit model. Radiology 1989; 171: 223-6.

  23. Holvoet P, Stassen JM, Hashimoto Y, Spriggs D, Devos P, Collen D. Binding properties of monoclonal antibodies against human fragment D-dimer of cross-linked fibrin to human plasma clots in an in vivo model in rabbits. Thromb Haemostas 1989; 61: 307-13.

  24. Juhan Vague I, Stassen JM, Alessi MC, Elias A, Aillaud MF, Serradimigni A, Collen D. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator. Semin Thromb Hemostas 1989; 15: 390-4.

  25. Spriggs DJ, Stassen JM, Hashimoto Y, Collen D. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits. Blood 1989; 73: 1207-12.

  26. Collen D, Dewerchin M, Rapold HJ, Lijnen HR, Stassen JM. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model. Circulation 1990; 82: 1744-53.

  27. Stassen JM, Vanlinthout I, Lijnen HR, Collen D. A hamster pulmonary embolism model for the evaluation of thrombolytic and pharmacokinetic properties of thrombolytic agents. Fibrinolysis 1990; 4 (suppl): 15-21.

  28. Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 1991; 84: 1216-34.

  29. Collen D, Lijnen HR, Vanlinthout I, Kieckens L, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of human tissue-type plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains, in a hamster pulmonary embolism model. Thromb Haemostas 1991; 65: 174-80.

  30. Dewerchin M, Lijnen HR, Stassen JM, De Cock F, Quertermous T, Ginsberg MH, Plow EF, Collen D. Effect of chemical conjugation of recombinant single-chain urokinase-type plasminogen activator with monoclonal antiplatelet antibodies on platelet aggregation and on plasma clot lysis in vitro and in vivo. Blood 1991; 78: 1005-18.

  31. Kurokawa T, Iwasa S, Kakinuma A, Stassen JM, Lijnen HR, Collen D. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator. Thromb Haemostas 1991; 66: 684-93.

  32. Laroche Y, Demaeyer M, Stassen JM, Gansemans Y, Demarsin E, Matthyssens G, Collen D, Holvoet P. Characterization of a recombinant single-chain molecule comprising the variable domains of a monoclonal antibody specific for human fibrin fragment D-dimer. J Biol Chem 1991; 266: 16343-9.

  33. Lijnen HR, Stassen JM, Vanlinthout I, Fukao H, Okada K, Matsuo O, Collen D. Comparative fibrinolytic properties of staphylokinase and streptokinase in animal models of venous thrombosis. Thromb Haemostas 1991; 66: 468-73.

  34. Lu HR, Lijnen HR, Stassen JM, Collen D. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model. Blood 1991; 78: 125-31.

  35. Stassen JM, Lijnen HR, Kieckens L, Collen D. Small animal thrombosis models for the evaluation of thrombolytic agents. Circulation 1991; 83: IV65-72.

  36. Stassen JM, Lijnen HR, Vanlinthout I, Collen D. Thrombolysis with bolus injections and infusions of tissue-type plasminogen activator in rabbits with experimental jugular vein thrombosis. Fibrinolysis 1991; 5: 165-70.

  37. Bulens F, Thompson EA, Stassen JM, Moreau H,Declerck PJ, Nelles L, Collen D. Induction of t-PA synthesis with intravenous bolus injection of vitamin A palmitate in vitamin A deficient rats. Fibrinolysis 1992; 6: 243-9.

  38. Collen D, De Cock F, Vanlinthout I, Declerck PJ, Lijnen HR, Stassen JM. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 1992; 6: 232-42.

  39. Dewerchin M, Vandamme AM, Holvoet P, De Cock F, Lemmens G, Lijnen HR, Stassen JM, Collen D. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated singlechain urokinase. Thromb Haemostas 1992; 68: 170-9.

  40. Imura Y, Stassen JM, Bunting S, Stockmans F, Collen D. Antithrombotic properties of L-cysteine, N-(mercaptoacetyl)-D-Tyr-Arg-Gly-Asp-sulfoxide (G4120) in a hamster platelet-rich femoral vein thrombosis model. Blood 1992; 80: 1247-53.

  41. Imura Y, Stassen JM, Collen D. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharmacol Exp Ther 1992; 261: 895-8.

  42. Imura Y, Stassen JM, Kurokawa T, Iwasa S, Lijnen HR, Collen D. Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons. Blood 1992; 79: 2322-9.

  43. Imura Y, Stassen JM, Vreys I, Lesaffre E, Gold HK, Collen D. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Thromb Haemostas 1992; 68: 336-40.

  44. Li XK, Lijnen HR, Nelles L, Van Hoef B, Stassen JM, Collen D. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1. Blood 1992; 79: 417-29.

  45. Lijnen HR, Webb PD, Van Hoef B, De Cock F, Stassen JM, Prior SD, Collen D. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line. Thromb Haemostas 1992; 67: 239-47.

  46. Lijnen HR, Stassen JM, Rapold HJ, Nakamura H, Kobayashi Y, Collen D. Biochemical and biological properties of a recombinant chimera consisting of amino acids Asn-1 to Lys-22 of alpha2-antiplasmin (fibrin cross-linking site) and amino acids Leu-4 to Leu-411 of single chain urokinase-typa plasminogen activator. Fibrinolysis 1992; 6: 87-98.

  47. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, Mulligan RC, Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 1993; 92: 2756-60.

  48. Collen D, De Cock F, Stassen JM. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation 1993; 87: 996-1006.

  49. Collen D, De Mol M, Demarsin E, De Cock F, Stassen JM. Isolation and conditioning of recombinant staphylokinase for use in man. Fibrinolysis 1993; 7: 242-7.

  50. Holvoet P, Dewerchin M, Stassen JM, Lijnen HR, Tollenaere T, Gaffney PJ, Collen D. Thrombolytic profiles of clot-targeted plasminogen activators. Parameters determining potency and initial and maximal rates. Circulation 1993; 87: 1007-16.

  51. Holvoet P, Laroche Y, Stassen JM, Lijnen HR, Van Hoef B, De Cock F, Van Houtven A, Gansemans Y, Matthyssens G, Collen D. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. Blood 1993; 81: 696-703.

  52. Stassen JM, Rapold HJ, Vanlinthout I, Collen D. Comparative effects of enoxaparin and heparin on arterial and venous clot lysis with alteplase in dogs. Thromb Haemostas 1993; 69: 454-9.

  53. Stassen JM, Collen D. In vivo models for experimental thrombolysis. Fibrinolysis 1993; 7, S1: 39.

  54. Collen D, Lijnen HR, Stassen JM. Combination of animal models and biotechnologies in the development of new thrombolytic agents. Fibrinolysis 1993; 7, S1: 36-43.

  55. Carmeliet P, Schoonjans L, Kieckens L, Stassen JM, Bronson R, Collen D, Mulligan R. Biological effects of inactivation of the gens for tissue-type plasminogen activator, urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in mice. Fibrinolysis 1993; 7, S1: 27-28.

  56. Collen D, Lu HR, Stassen JM, Vreys I, Yasuda T, Bunting S, Gold HK. Antithrombotic effects and bleeding time prolongation with synthetic platelet GPIIb/IIa inhibitors in animal models of platelet-mediated thrombosis. Thromb Haemostas 1994; 71: 95-102.

  57. Collen D, Stassen JM, Yasuda T, Refino CJ, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemostas 1994; 72: 98-104.

  58. Kiss RG, Stassen JM, Deckmyn H, Roskams T, Gold HK, Plow EF, Collen D. Contribution of platelets and the vessel wall to the antithrombotic effects of a single bolus injection of Fab fragments of the antiplatelet GPIIb/IIIa antibody 7E3 in a canine arterial eversion graft preparation. Arterioscler Thromb 1994; 14: 375-80.

  59. Vanderschueren SMF, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and animal models. Thromb Haemostas 1994; 72: 297-301.

  60. Matsuno H, Stassen JM, Vermylen J, Deckmyn H: Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima fomation. Circulation 1994; 90: 2203-2206.

  61. Harsfalvi J, Stassen JM, Hoylaerts M, Van Houtte E, Sawyer RT, Vermylen J, Deckmyn H: Calin from hirudo medicinalis, an inhibitor of von willebrand factor binding to collagen under static and flow conditions. Blood 1995; 85: 705-711.

  62. Deckmyn H, Stassen JM, Vreys I, Van Houtte E, Sawyer RT, Vermylen J: Calin from Hirudo medicinalis, an inhibitor of platelet adhesion to collagen, prevents platelet-rich thrombosis in hamsters. Blood 1995; 85: 712-719.

  63. Stassen JM, Nyström Å, Hoylaerts MF, Collen D. Antithrombotic effects of thrombolytic agents in a platelet-rich femoral vein thrombosis model in hamsters. Circulation 1995; 91: 1330-1335.

  64. Stassen JM, Lü G, Andreén O, Nyström E, Nyström Å: Intraoperative thrombolytic treatment of microarterial occlusion by selective rt-PA infusion. Plast Reconstr Surg 1995; 96: 1215-1217.

  65. Stassen JM, Lambeir AM, Vreys I, Laroche Y, Mathyssens G, Nyström A, Sixma JJ, Vermylen J: Characterization of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties. Thromb Haemostas 1995; 74:646-654.

  66. Stassen JM, Lambeir AM, Vreys I, Deckmyn H, Mathyssens G, Nyström A, Vermylen J: Characterization of a novel series of aprotinin-derived anticoagulants. II.Comparative antithrombotic effects on platelet-rich thrombus formation in hamsters. Thromb Haemostas 1995; 74:655-659.

  67. Badenhorst PN, Kotze HF, Lamprecht S, Meiring M, Van Wyck V, Nuyts K, Stassen JM, Vermylen J, Deckmyn H: Prolonged inhibition of acute arterial thrombosis by high dosing of a monoclonal anti-platelet glycoprotein IIb/IIIa antibody in a baboon model. Thromb Haemostas 1995; 74: 751-757.

  68. Matsuno H, Stassen,JM, Hoylaerts M, Vermylen J, Deckmyn H. Fast and reproducible vascular neointima formation in the hamster carotid artery: Effects of trapedil and captopril. Thromb Haemostas 1995; 74,1591-1596.

  69. Stassen JM, Nyström Å. Invited Discussion. Effect of anticoagulation and inhibition of platelet aggregation on arterial versus venous thrombosis. Ann Plast Surg 1995; 35: 169-170.

  70. Vanderschueren S, Stassen JM, Collen D. Comparative immunogenicity of recombinant wild-type staphylokinase and a selected mutant (SakSTAR.M38) in a baboon thrombolysis model. J Cardiovasc Pharmacol 1996; 27: 809-815.

  71. Matsuno H, Stassen JM, Moons L, Vermylen J, Hoylaerts MF: Neointima formation in injured hamster carotid artery is effectively prevented by the combination of G4120 and Quinapril. Thromb Haemostas 1996; 76: 263-269.

  72. Nong ZX, Stassen JM, Moons L, Collen D, Janssens S. Tissue specific ACE-inhibition with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodelling. Circulation 1996; 94: 1941-1947.

  73. Hoylaerts MF, Thys C, Stassen JM, Vermylen J. Dose-responses to inducers and inhibitors of platelet aggregation analysed via a micro-method. Blood Coagul Fibrinolysis 1996; 7: 187-190.

  74. Stockmans F, Stassen JM, Vermylen J, Hoylaerts M, Nyström Å. A technique to investigate mural thrombus formation in small arteries and veins: I: Comparative morphometric and histological analysis. Ann Plast Surg 1997; 38: 55-62.

  75. Stockmans F, Stassen JM, Vermylen J, Hoylaerts M, Nyström Å. A technique to investigate mural thrombus formation in small arteries and veins: II: Effects of aspirin, heparin r-hirudin and G-4120. Ann Plast Surg 1997; 38: 63-68.

  76. Carmeliet P, Moons L, Stassen JM, De Mol M, Bouche A, Van den Oord JJ, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol 1997; 150: 761-776.

  77. Carmeliet P, Stassen JM, Van Vlaenderen I, Meidell RS, Collen D, Gerard RD. Adenovirus-mediated transfer of tissue-type plasminogen activator augments thrombolysis in tissue-type plasminogen activator-deficient and plasminogen activator inhibitor-1-overexpressing mice. Blood 1997; 90: 1527-1534.

  78. Stassen JM. Animal models to assess the safety and efficacy of thrombolytic agents. In Sasahara A, Loscalzo J (eds): New therapeutic agents in thrombosis and thrombolysis, New York, Marcel Dekker Inc., 1997, 451-474.

  79. Stassen JM, Nyström Å. A historical review on thrombosis and hemostasis. Ann Plast Surgery 1997; 39: 317-329.

  80. Yamamoto H, Vreys I, Stassen JM, Yoshimoto R, Vermylen J, Hoylaerts MF. Antagonism vWF inhibits both injury induced arterial and venous thrombosis in the hamster. Thromb Haemost 1998; 79: 202-210.

  81. Stockmans F, Deberdt W, Nystrom Å, Nystrom E, Stassen JM, Vermylen J, Deckmyn H. Inhibitory effect of piracetam on platelet-rich thrombus formation in an animal model. Thromb haemost 1998; 79: 222-227.

  82. Holvoet P, Stassen JM, Van Cleemput J, Collen D, Vanhaecke J. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18:100-107.

  83. Nar H, Bauer M, Stassen JM, Lang D, Gils A, Declerck PJ. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol. 2000; 297:683-95.

  84. Bijnens AP, Gils A, Knockaert I, Stassen JM, Declerck PJ. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies. J Biol Chem. 2000; 275:6375-80.

  85. Wu D, Stassen JM, Seidler R, Doods H. Effects of BIIB513 on ischemia-induced arrhythmias and myocardial infarction in anesthetized rats. Basic Res Cardiol 2000; 95: 449-456.

  86. Nar H, Bauer M, Schmid A, Stassen JM, Wienen W, Priepke HWM., Iris K. Kauffmann IK, Ries UJ, Hauel NH. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. Structure 2001; 9:29–37.

  87. Bijnens AP, Ngo TH, Gils A, Dewaele J, Knockaert I, Stassen JM, Declerck PJ. Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1. Thromb Haemost. 2001; 85:866-74.

  88. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhbitors. J. Med. Chem. 2002; 45:1757-1766.

  89. Gils A, Stassen JM, Nar H, Kley JT, Wienen W, Ries UJ, Declerck PJ. Characterization and comparative evaluation of a novel PAI-1 inhibitor. Thromb Haemost. 2002;88:137-143.

  90. Ngo T-H, Zhou Y, Stassen JM, Declerck PJ. Importance of N-terminal residues in plasminogen activator inhibitor 1 on its antibody induced latency transition. Thromb Haemost. 2002;88:288.

  91. Verbeke K, Gils A, Stassen JM, Declerck PJ. Elucidation of the paratope of scFv-8H9D4, a PAI-1 neutralizing antibody derivative. Thromb Haemost. 2003;89:74-82.

  92. Ries UJ, Priepke HW, Hauel NH, Haaksma EE, Stassen JM, Wienen W, Nar H. Heterocyclic thrombin inhibitors. Part 1: design and synthesis of amidino-phenoxy quinoline derivatives. Bioorg Med Chem Lett. 2003;13:2291-5.

  93. Ries UJ, Priepke HW, Hauel NH, Handschuh S, Mihm G, Stassen JM, Wienen W, Nar H. Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agents. Bioorg Med Chem Lett. 2003;13:2297-302.

  94. Stassen JM, Ries,UJ. Preface [Hot Topic: Anticoagulation: Current and Future Therapies (Guest Editors: Stassen JM /)] Curr Med Chem 2004;11: pp. i-i(1).

  95. Stassen JM, Arnout J, Deckmyn H. The hemostatic system.Curr Med Chem 2004;11:2245-60.

  96. Stassen JM, Ries,UJ. Preface [Hot Topic: Anticoagulation: Current and Future Therapies (Guest Editors: Stassen JM /)] Curr Med Chem 2004;11: pp. i-i(1).

  97. Staelens S, Desmet J, Ngo TH, Vauterin S, Pareyn I, Barbeaux P, Van Rompaey I, Stassen JM, Deckmyn H, Vanhoorelbeke K. Humanization by variable domain resurfacing and grafting on a human IgG(4), using a new approach for determination of non-human like surface accessible framework residues based on homology modelling of variable domains. Mol Immunol. 2005 Aug 20; [Epub ahead of print]